To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05814523 |
|
Recruitment Status :
Withdrawn
(Business reasons)
First Posted : April 18, 2023
Last Update Posted : May 14, 2024
|
Sponsor:
Marinus Pharmaceuticals
Information provided by (Responsible Party):
Marinus Pharmaceuticals
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a multicenter, double-blind, randomized, placebo-controlled study that will evaluate the efficacy, safety, and tolerability of intravenous (IV) ganaxolone versus placebo co-administered with IV antiepileptic drug (AED) according to standard of care for the treatment of RSE. Approximately 70 participants will be randomized in a 1:1 ratio to receive ganaxolone IV solution or placebo IV solution along with standard of care (SOC) IV AED.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Refractory Status Epilepticus | Drug: Ganaxolone Drug: Placebo Drug: Standard of care | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 0 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus |
| Estimated Study Start Date : | March 2024 |
| Estimated Primary Completion Date : | August 2024 |
| Estimated Study Completion Date : | August 2024 |
Resource links provided by the National Library of Medicine
Drug Information
available for:
Ganaxolone
| Arm | Intervention/treatment |
|---|---|
| Experimental: Ganaxolone IV solution + SOC IV AED |
Drug: Ganaxolone
Ganaxolone will be administered as IV solution. Drug: Standard of care A non-anesthetic medication not previously used for treatment of SE within the current episode and will be administered at a dose sufficient for the termination of SE according to investigator judgment. |
| Experimental: Placebo IV solution + SOC IV AED |
Drug: Placebo
Placebo will be administered as IV solution. Drug: Standard of care A non-anesthetic medication not previously used for treatment of SE within the current episode and will be administered at a dose sufficient for the termination of SE according to investigator judgment. |
Primary Outcome Measures :
- Percentage of participants who will report cessation of SE within 30 minutes of investigational product (IP) initiation of at least 30 minutes duration [ Time Frame: Up to 30 minutes ]Status epilepticus cessation will be determined by the investigator based on clinical and electroencephalography (EEG) features
- Percentage of participants who will report no escalation of treatment for persistent or recurrent SE within 36 hours of IP initiation [ Time Frame: Up to 36 hours ]
Secondary Outcome Measures :
- Percentage of participants who will report cessation of SE within 30 minutes of IP initiation of at least 30 minutes duration [ Time Frame: Up to 30 minutes ]
- Percentage of participants who will report no escalation of treatment for persistent or recurrent SE within 72 hours of IP initiation [ Time Frame: Up to 72 hours ]
- Time to SE cessation [ Time Frame: Up to 72 hours ]
- Percentage of participants having cessation of SE within 30 minutes of IP initiation of at least 30 minutes duration without escalation of treatment [ Time Frame: Up to 30 minutes ]
- Percentage of participants reporting no escalation of treatment for persistent or recurrent SE within 36 hours of IP initiation [ Time Frame: Up to 36 hours ]
- Percentage of participants reporting no escalation of treatment for persistent or recurrent SE within 72 hours of IP initiation [ Time Frame: Up to 72 hours ]
- Change from Baseline in Modified Rankin Scale (mRS) at the time of hospital discharge [ Time Frame: Baseline and Up to Day 31 ]The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death where 0 - No symptoms; 1=No significant disability. Able to carry out all usual activities, despite some symptoms; 2=Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities; 3=Moderate disability. Requires some help, but able to walk unassisted; 4=Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted; 5=Severe disability. Requires constant nursing care and attention, bedridden, incontinent; 6=Dead. Higher scores will indicate high degree of disability.
- Change from Baseline in level of responsiveness as assessed by the Full Outline of UnResponsiveness (FOUR) Score scale [ Time Frame: Baseline and at 24, 36 and 72 hours ]The FOUR Score is a 17-point scale (with potential scores ranging from 0 - 16). Decreasing FOUR Score is associated with worsening level of consciousness. The FOUR coma scale includes 4 parameters with a minimum score of 0 and a maximum score of "4" for each of them: eye reactions (eye opening and tracking), motor responses (pain response and simple commands), stem reflexes (pupillary, corneal and cough) and respiratory patterns (respiratory rhythm and respiratory attempts in patients on a ventilator). The points are summed up, their sum is estimated. The interpretation of results will be as 15 to 16 score: clear consciousness; Less than 15: Impairment of consciousness; from 4 to 8: Coma and 0-4: Death. Lower the score, the greater the coma gravity.
- Change from Baseline in level of sedation/ agitation as assessed by Richmond Agitation and Sedation Scale (RASS) [ Time Frame: Baseline and at 24, 36 and 72 hours ]The RASS is a medical scale used to measure the agitation or sedation level. It is a 10-point scale that ranges from -5 to +4 with -5=unarousable and +4=combative. Zero means the patient is alert and calm. higher scores indicate more agitation.
- Percentage of participants with mRS > 3 at the time of hospital discharge [ Time Frame: Up to 122 hours ]The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death where 0 - No symptoms; 1=No significant disability. Able to carry out all usual activities, despite some symptoms. 2=Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3=Moderate disability. Requires some help, but able to walk unassisted. 4=Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5=Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6=Dead. Higher scores will indicate high degree of disability.
- Change from Baseline in Clinical Global Impression-Improvement (CGI-I) following IP initiation and at hospital discharge [ Time Frame: Baseline and at 24, 36, and 72 hours ]The CGI-I is a 7-point Likert scale that the parent(s)/caregiver(s)/legally authorized representative (LAR)(s) and clinician uses to rate the change in overall seizure control, behavior, safety, and tolerability after initiation of the IP relative to Baseline (prior to treatment with the IP). It was rated as: 1- "very much improved", 2- "much improved', 3- "minimally improved", 4- "no change", 5- "minimally worse", 6- "much worse", and 7- "very much worse". Higher scores indicated worse condition.
- Number of hours on positive pressure ventilation attributable to the episode of SE or its treatment [ Time Frame: Up to 4 Weeks ]Healthcare Utilization Questionnaires include the Hospitalization Questionnaire and the Positive Pressure Ventilation (PPV) and Intubation Questionnaire. The Hospitalization Questionnaire should be collected at hospital discharge or at final study visit/contact. The need for non-invasive or invasive ventilatory support within 24 hours prior to IP initiation and following IP initiation and within 48 hours following IP discontinuation should be collected as close as possible to the event.
- Number of hours on positive pressure ventilation [ Time Frame: Up to 4 Weeks ]
- Length of stay (days) in intensive care unit (ICU) [ Time Frame: Up to 4 Weeks ]
- Length of stay (days) in hospital [ Time Frame: Up to 4 Weeks ]
- Percentage of participants requiring artificial ventilation after initiation of IP [ Time Frame: Up to 122 hours ]
- Percentage of participants not requiring IV anesthesia for SE treatment within 36 hours of IP initiation [ Time Frame: Up to 36 hours ]
- Percentage of participants not requiring IV anesthesia for SE treatment within 72 hours of IP initiation [ Time Frame: Up to 72 hours ]
- Percentage of participants not requiring IV anesthesia for SE treatment through the final study follow-up visit/contact [ Time Frame: Up to 4 Weeks ]
- Percentage of participants who do not develop super refractory status epilepticus (SRSE) through the final study follow-up visit/contact [ Time Frame: Up to 4 Weeks ]
- Change from Baseline in Euro Quality of Life (five-level EuroQoL five-dimensional [EQ-5D-5L]) score [ Time Frame: Baseline and Up to 4 Weeks ]The EQ-5D-5L is the EuroQoL 5D-5L, a descriptive system that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The participant is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the participant's health state. A positive score means quality of life improvement, a negative score, a worsening of quality of life. Higher scores indicate more problems.
- Number of AEDs at discharge [ Time Frame: Up to 122 hours ]
- Percentage of participants requiring supplemental oxygen after initiation of IP [ Time Frame: Up to 4 Weeks ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Participant, participant's parent, guardian, or LAR must provide signed informed consent/assent, and once capable (per institution guidelines), there must be documentation of consent/assent by the participant demonstrating they are willing and aware of the investigational nature of the study and related procedures. Where allowed by law, where the participant lacks the capacity to make informed decisions regarding his/her medical treatment options, the treating clinician may follow their deferred consenting practices. The clinician will make the final decision based on the best interests of the participant.
- Male or females 18 years of age and older at the time of the first dose of IP.
-
SE warranting imminent progression of treatment meeting the following criteria:
a) A diagnosis of SE, warranting imminent progression of treatment for seizure control, with or without prominent motor features based on clinical and EEG findings:
i. Diagnosis is established by:
- For SE with prominent motor features: Clinical and EEG seizure activity indicative of convulsive, myoclonic, or focal motor SE.
- For SE without prominent motor features (nonconvulsive SE): Appropriate clinical features and an EEG indicative of non-convulsive status epilepticus (NCSE).
ii. For any type of SE:
- At least 6 minutes of cumulative seizure activity over a 30-minute period within the hour before IP initiation, AND Seizure activity during the 30 minutes immediately prior to IP initiation.
-
Participants must have received a benzodiazepine and at least 1 of the following IV AEDs for treatment of the current episode of SE administered at an adequate dose and for a sufficient duration, in the judgement of the investigator, to demonstrate efficacy. The benzodiazepine and at least 1 of the IV AEDs must have been administered at a dose that would be expected to be effective for the termination of the current episode of SE.
- IV Fosphenytoin/phenytoin,
- IV Valproic acid,
- IV Levetiracetam,
- IV Lacosamide,
- IV Brivaracetam, or
- IV Phenobarbital.
- Body mass index (BMI) < 40 or, if BMI is not able to be calculated at screening, participant is assessed by investigator as not morbidly obese.
Exclusion Criteria:
- Life expectancy of less than 24 hours.
- Anoxic brain injury or an uncorrected, rapidly reversable metabolic condition as the primary cause of SE (eg, hypoglycemia < 50 milligrams per deciliter [mg/dL] or hyperglycemia > 400 mg/dL).
- Participants who have received high-dose IV anesthetics (eg, midazolam, propofol, thiopental, or pentobarbital) during the current episode of SE for more than 18 hours, or who continue to have clinical or electrographic evidence of persistent seizures while receiving high-dose IV anesthetics.
- Clinical condition or advance directive that would NOT permit admission to the ICU or use of IV anesthesia.
- Participants known or suspected to be pregnant
- Participants with known allergy or sensitivity to progesterone or allopregnanolone medications/supplements
- Receiving a concomitant IV product containing Captisol.
- Known or suspected hepatic insufficiency or hepatic failure leading to impaired synthetic liver function.
- Known or suspected stage 3B (moderate to severe; estimated glomerular filtration rate [eGFR] 44-30 milliliters per minute per 1.73-meter square [mL/min/1.73m^2]), stage 4 (severe; eGFR 29-15 mL/min/1.73m^2), or stage 5 (kidney failure; eGFR < 15 mL/min/1.73m^2 or dialysis) kidney disease.
- Use of an investigational product for which less than 30 days or 5 half-lives have elapsed from the final product administration. Participation in a non-interventional clinical study does not exclude eligibility.
- Known or suspected history or evidence of a medical condition that, in the investigator's judgment, would expose a participant to an undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the study
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05814523
Locations
Show 52 study locations
Sponsors and Collaborators
Marinus Pharmaceuticals
| Responsible Party: | Marinus Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT05814523 |
| Other Study ID Numbers: |
1042-SE-3004 |
| First Posted: | April 18, 2023 Key Record Dates |
| Last Update Posted: | May 14, 2024 |
| Last Verified: | May 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Marinus Pharmaceuticals:
|
Refractory status epilepticus Ganaxolone Antiepileptic drug Standard of care |
Additional relevant MeSH terms:
|
Status Epilepticus Seizures Neurologic Manifestations Nervous System Diseases Ganaxolone Neurosteroids |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs GABA Modulators GABA Agents |